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INTRODUCTION
Preoperative chemoradiation therapy (CRT) has become the 
standard treatment for patients with locally advanced rectal 
cancer [1,2]. This treatment has been shown to improve survival 
and may reduce local recurrence rates. Many studies have 
suggested that a patient’s tumor regression grade is significantly 
associated with prognosis; specifically, patients with complete 
regression have a good prognosis [3,4]. However, 15%–30% of 
patients still progress while being treated with CRT or go on to 
develop distant metastasis [5-8]. Therefore, predicting tumor 
response before treatment can significantly influence the 
selection of patients for preoperative CRT as well as potentially 
modify postoperative treatment plans. However, the currently 
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Purpose: Preoperative chemoradiation therapy (CRT) has become the standard treatment for patients with locally ad-
vanced rectal cancer, 15%–30% of patients still progress while being treated with CRT. The aim of this study was to identify 
as important biomarker of poor response and evaluate the mechanism associated with CRT resistance. 
Methods: This study included 60 human colon tumour pre-irradiation specimens. Expressions of epidermal growth factor 
receptor (EGFR), p53, Krüppel-like factor 5 (KLF5), C-ern, Ki67 were assessed and correlated with tumor regression 
grades and complete remission. We added in vitro study with biomarker which has been identified as important biomarker 
of poor response to evaluate the mechanism associated with CRT resistance.
Results: Pathologic complete remission (pCR) was achieved by 9 patients (18%). EGFR and KLF5 were significantly as-
sociated with pCR (P = 0.048, P = 0.023, respectfully). And multivariate analysis showed high KLF5 intensity was worse 
factor for pCR (P = 0.012). In vitro study, radiation or chemotherapy therapy stabilized KLF5 protein levels in a time- and 
dose-depended manner in HCT116 and Caco-2 cells. KLF5 overexpression in HCT116 stable cell line showed significantly 
better cell viability by increasing cyclinD1 and b-catenin compared to control cells in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, suggesting that KLF5 mediates cell survival. 
Conclusion: KLF5 was significantly associated with the presence of KRAS mutations, and KLF5 was an independent poor 
response predictor of CRT in rectal cancer. Our study is pilot study and more research will be needed in the future.
[Ann Surg Treat Res 2019;97(2):83-92]
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available imaging modalities, including endorectal ultrasound, 
CT, MRI, or positron emission tomography used to restage 
patients after preoperative CRT lack the accuracy needed for 
this prediction [9,10]. For this reason, oncologists have a great 
interest in identifying molecular predictors of rectal cancer 
response to CRT [11,12]. Many molecular markers have been 
investigated, but as yet, the availability of markers able to 
predict CRT response is lacking. 
Recently Hur et al. [13] reported that incorporating multiple 
significant prognostic factors could increase the accuracy of 
predicting tumor response to CRT. In other words, one factor 
alone cannot explain or predict tumor response to CRT, 
suggesting that determining the detailed mechanism of tumor 
response to CRT is necessary. 
The aim of this study was to determine useful predictive 
marker of tumor response to patients using biopsy im-
munohistochemistry (IHC) before irradiation. Furthermore, we 
added in-vitro study with biomarker which has been identified 
as important biomarker of poor response to evaluate the 
mechanism associated with CRT resistance.
METHODS
Patient selection 
From March 2015 to January 2016, four multicenter 60 con-
secutive patients who received neoadjuvant chemoradiation 
for locally advanced (radiological T3–4 or N+ and/or clinically 
bulky) rectal cancer were enrolled in this study. Patients with 
distant metastases, recurrent disease, previous chemotherapy, 
pelvic radiotherapy, abnormal liver, kidney, or bone marrow 
function, or those aged less than 18 years or more than 80 
years, were excluded. The study was approved by the scientific 
review and ethics committee at our institution. Written in-
formed consent was obtained from all the patients before the 
study. The initial clinical stage was based on a digital rectal 
examination, rigid proctoscopy, abdominopelvic CT, pelvic 
magnetic resonance imaging, chest CT, whole-body positron 
emission tomography/CT, complete blood cell count, liver 
function tests, and the serum CEA level. The location of the 
tumor was defined as the distance between the caudal margin 
of the tumor and the anal verge, and this was measured by 
a digital examination and rigid proctoscopy. A biopsy was 
performed before starting CRT. Approval for all research-related 
activities was obtained from the Institutional Review Board of 
the Hallym University (approval number: 2019-05-002).
Preoperative CRT protocol
All patients received a total dose of 50.4 Gy with daily 
fractions of 180 cGy/d over 5 weeks. Chemotherapy was 
administered intravenously, consisting of 5-fluorouracil (5-
FU; 425 mg/m2/day) and leucovorin (20 mg/m2/day) during the 
first and fifth weeks of radiotherapy. Experienced surgeons 
performed the radical surgery, which included total mesorectal 
excision, high vascular ligation (the inferior mesenteric artery 
and vein), and en bloc resection of the adjacent involved 
organs, 6 to 8 weeks following the completion of preoperative 
chemoradiation.
Tumor regression grading
The surgery included low anterior resection with colorectal 
or coloanal anastomosis and abdominoperineal resection. Use 
of a diverting stoma was subject to the surgeon’s decision. The 
disease staging was based on the final pathological features 
of the tumor according to the seventh Union for International 
Cancer Control TNM staging system. Two experienced gas-
trointestinal pathologists read the results of the pathology 
collected from the 4 institutions according to the pathologic 
TNM staging and the tumor regression grading (TRG) systems 
based on the ratio of fibrosis to residual cancer [14]. TRG scores 
were defined as follows: TRG1 (fibrosis <25%), TRG2 (25%≤ 
fibrosis <50%), TRG3 (50%≤ fibrosis), and TRG4 (complete 
remission). 
Immunohistochemical staining 
With pilot study, we selected biomarkers that differed more 
than 4 fold in mRNA levels in TRG4 and TRG1. Epidermal 
growth factor receptor (EGFR), C-ern and Ki67 and Krüppel-
like factor 5 (KLF5), known as a transcriptional factor acting 
down-stream of RAS-MAPK cascade, were selected [15-18]. 
Biopsy slides were blocked with 5% bovine serum albumin 
in phosphate buffered saline (PBS) and primary antibodies 
(Abcam, Ltd., Cambridge, United Kingdom) were applied at a 1:50 
dilution, followed by incubation with biotinylated anti-rabbit 
secondary antibody (Dianova, Hamburg, Germany, at a dilution 
of 1:50). With EGFR, C-ern, the intensity immunostaining was 
scored as: 1+ (weak), 2+ (moderate), and 3+ (intense). With 
Ki67 and KLF5, the percentage of positive tumor cells and 
staining intensity were then multiplied to produce a weighted 
score for each case ranging from 0 to 12; ‘‘low expression’’ was 
classified as a score of 5 or below and ‘‘high expression’’ as a 
score of 6 or above.
In vitro study
Cell culture
The human colorectal adenocarcinoma cell lines, SW48, 
HCT116 p53+/+, HCT116 p53-/-, Caco-2, DLD-1, and HT-29 were 
obtained from the American Type Culture Collection (LGC-
Promochem, Wiesbaden, Germany). SNU-C4 5-FU-sensitive cell 
line and SNU-C4 5-FU-resistant cell line (which was generated 
by exposing cells to 5-FU for more than 6 months to create 
stable cell lines resistant to 5-FU), were obtained from Korean 
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cell line bank (Seoul, Korea). The cells were maintained in 
Dulbecco’s modified eagle medium (Biochrom, Berlin, Germany) 
and supplemented with 10% heat-inactivated fetal calf serum, 
1% sodium pyruvate, and 2 mmol/L glutamine (all supplements 
from Biochrom) at 37℃, 5% CO2, and 95% humidity. 
Western immunoblotting
For immunoblotting, cells were washed and lysed in 
radioimmunoprecipitation assay buffer (50 mmol/L Tris [pH, 
7.4], 150 mmol/L NaCl, 1% Triton X-100, 1% deoxycholate) 
supplemented with protease inhibitors (1-mmol / L 
phenylmethylsulfonylfluoride, 10-ag/mL pepstatin, 10-ag/mL 
aprotinin, and 5-ag/mL leupeptin; all from Sigma, Deisenhofen, 
Germany). Protein concentrations were determined using 
the bicinchoninic acid protein assay (Pierce, Rockford, IL). 
Equal amounts of protein (10 ag) were separated on a 12.5% 
sodium dodecyl sulfate polyacrylamide gel and transferred to 
a nitrocellulose membrane (Hybond C, Amersham, Freiburg, 
Germany). Membranes were blocked in 5% nonfat dry milk 
in PBS for 30 minutes at room temperature and probed with 
rabbit anti-KLF5, KRAS, cyclin D1, b-catenin, a-tubulin, Trp53, 
P21, Bax, or PUMA antibodies (dilution, 1:1,000, R&D Systems, 
Wiesbaden, Germany) overnight at 4℃. Next, membranes 
were incubated with horseradish peroxidase-linked secondary 
antibodies (1:200, Dako, Hamburg, Germany) and developed 
by an enhanced chemoluminescence detection system (ECL, 
Amersham) and autoradiography (Biomax film, Kodak, 
Rochester, MN). To confirm equal protein loading, membranes 
were subsequently reprobed with a 1:2,000 dilution of an 
anti-h-tubulin antibody (Biozol, Eching, Germany) or GAPDH 
(Biozol, Eching, Germany). For densitometric analysis, scanned 
autoradiographs were quantified using the AIDA software 
package (Raytest, Straubenstadt, Germany).
Biomarker overexpression stable cell line 
For stable overexpression of the biomarker gene, the fragment 
encoding the full-length cDNA from the pSG5-vector construct 
was cloned into the SmaI-XhoI sites of pLL-CMV-puro lentiviral 
vector. Plasmid DNAs were transfected into HCT116 cells along 
with lentiviral packaging mix consisting of an envelope and 
packaging vector to produce lentivirus packed with biomarker 
cDNA.
MTT assay
Suspension cells were harvested by centrifugation for 5 
minutes at 6℃. The cell was washed by resuspending in 5 mL 
sterile PBS. Then the cells were diluted from 5 × 106 to 5 × 
103 cells/mL. The cells were incubated for 12 hours. And then 
10 L of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reagent were added to each well. When purple 
precipitate is clearly visible, waiting 2 more hours, we measured 
the absorbance of the wells, including the blanks, at 570 nm. 
Statistical analysis 
Statistical evaluation was carried out using the SPSS ver. 15.0 
(SPSS Inc., Chicago, IL, USA). Tumor regression and N down 
grading were tested with the chi-square test. The pathologic 
complete remission study was analyzed with binary logistic 
regression method. Comparison of factors to KLF5 scoring was 
used with t-test. A value of P < 0.05 was considered statistically 
significant. 
RESULTS
Characteristics of patients 
The patient’s demographics were tabulated (Table 1). A total 
of 60 patients were included in this study, 49 males and 11 
females. The median age of the patients was 59 ± 18.3 years 
(range, 35–79 years), and the median distance of the tumor 
from the anal verge was 7.3 ± 3.1 cm. Thirty-four patients 
(56.7%) exhibited a poor response to CRT (TRG 1 or 2), whereas 
26 patients (43.3%) exhibited a good response (TRG 3 or 4). A 
Table 1. Patients characteristics (n = 60)
Characteristic Value
Age (yr) 59 ± 18.3
Sex
   Male 49 (81.7)
   Female 11 (18.3)
CEA (ng)
   ≤5 36 (60)
   >5 24 (40)
cT stage
   cT3 50 (83.3)
   cT4 10 (16.7)
cN stage
   cN0 31 (51.7)
   cN+ 29 (48.3)
Anal verge 7.3 ± 3.1
Complete response
   pCR 9 (15)
Tumor regression grade
   TRG 1–2 34 (56.7)
   TRG 3–4 26 (43.3)
TNM stage
   ypT0N0 9 (15)
   ypT1N0 14 (23.3)
   ypT2N0 17 (28.3)
   ypT3N0 22 (36.6)
   ypT4N1 8 (13.3)
Values are presented as mean ± standard deviation or number (%).
cT, clinal T­staging; cN, clinical N­staging; pCR, pathologic 
complete remission; TRG, tumor regression grade.
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pathologic complete response (pCR) was observed in 9 patients 
(15%). 
TRG according to biomarkers
Tumors of 8 of the patients (13.3%) harbored a KRAS mutation. 
The p53 expression observed 31 patients (51,6%), High KLF5 
expression observed 36 patients (60%). High KLF5 expression 
and p53 mutation were significantly associated with poor 
response of CRT (TRG 1 or 2) (P = 0.004, P = 0.021, respectfully) 
(Table 2). Additionally, a trend towards an association between 
KRAS mutation status and tumor regression was observed but 
was not statistically significant (P = 0.062). 
Correlation of clinical factors with pCR
Clinical factors, as well as the protein expression of several 
tumor-related markers, were evaluated to determine association 
with pCR (Table 3). By univariate analysis, high EGFR and KLF5 
expression were found to significantly correlate with failure of 
pCR (P = 0.048, P = 0.023); however, after multivariate analysis, 
only KLF5 expression still had significance as a poor prognostic 
factor. 
Comparison of clinicopathologic factors according 
to KLF5 intensity
Because KLF5 was determined to correlate with tumor 
response to treatment, we compared KLF5 expression to 
several clinical characteristics known to effect tumor response, 
including ypT and ypN stages, KRAS mutation status, pre-CEA, 
and TNM stage (Table 4). The high intensity of IHC staining of 
KLF5 significantly correlated with increasing ypT staging (P = 
0.009) and high related tendency with KRAS mutation status 
(P = 0.055).
In vitro study 
KLF5 expression in colon cancer cell line
We examined 6 different human colorectal cancer cell 
lines for mutated KRAS, mutated BRAF and KLF5 expression. 
Through DNA sequencing, we determined that DLD-1, SW-48, 
HCT116 p53+/+, and HCT116 p53-/- contained KRAS activating 
mutations, while HT-29 and CaCo-2 contained wild-type KRAS. 
Only HT-29 contained a BRAF mutation. The level of KLF5 
expression in the 6 cell lines correlated with KRAS genotype, 
with those containing mutated KRAS having higher levels. It is 
of interest to note that HT-29, which contains a mutated BRAF 
gene, exhibited higher levels of KLF5, similar to those cell lines 
harboring KRAS mutations. KRAS wild-type cell lines, SW48 
and CaC02, had low levels of cyclin D1 and b-catenin, as well 
as low levels of KLF5. Conversely, HCT116 p53+/+ and HCT116 
p53-/-, cell lines with activating KRASG13D mutations, exhibited 
higher levels of KLF5, cyclin D1 and b-catenin (Fig. 1A). 
The protein expressed at the downstream of KLF5 with KRAS 
mutation cell line or without KRAS mutation cell line  
We evaluated the (cyclin D1, b-catenin) protein known as 
expressed at the downstream of KLF5 expression. The cell line 
with KRAS mutation such as HCT116+/+ or HCT116-/-, high 
KLF5 expression, high cyclin D1 and high b-catenin expression 
was shown sequentially. However, the cell line without KRAS 
mutation such SW480, CaC02 showed low KLF5 expression 
and cyclin D1 and b-catenin expressed in proportion to KLF5 
expression (Fig. 1B). 
The increase in KLF5 expression depends on chemoradiation 
therapy 
To determine the effect of chemotherapy and radiation ther-
apy on KLF, we selected Caco-2 (without KRAS mutation) and 
HCT116 cell line (with KRAS mutation) which have endogenous 
KLF5 protein. We compared KLF protein expression in HCT 
116 (KRASG13D) cells treated with radiation (0, 2, 5, 10, 20 Gy). 
Additionally, we compared KLF expression in Caco-2 cell (wild-
type KRAS) treated with or without 5-FU (Fig. 2B). We found 
that KLF5 protein levels increased soon after DNA damage: 
levels were maximal after 10 Gy of radiation in HCT116. 
Similarly, in HCT116 cell, KLF5 protein levels were maximal 24 
hours after 10 nM 5-FU treatment in Caco-2 (Fig. 2A).
Additionally, we evaluated the changes of KLF5 protein 
Table 2. The biomarker expression in tumor tissue for as­
sessment of tumor regression grade and down grading
Variable No.
Tumor regression grade
TRG 1–2 TRG 3–4 P­value
EGFR
   N/1+ 44 22 22 0.140
   2+/3+ 16 12 4
Ki67
   High 44 26 18 0.568
   Low 16 8 8
C­ern
   N/1+ 49 30 19 0.18
   2+/3+ 11 4 7
p53
   Positive 31 18 13 0.021
   Negative 29 8 21
KLF5
   High 36 26 10 0.004
   Low 24 8 16
KRAS
   Wild type 52 27 25 0.062
   Mutation 8 7 1
TRG, tumor regression grading; EGFR, epidermal growth factor 
receptor; KLF, Krüppel­like factor.
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expression levels between SNU-C4 and SNU-C4 5-FU. SNU-C4 
5-FU is a stable cell line that has been subjected to long-term 
exposure of 5-FU and as a result, has developed 5-FU resistance 
(Fig. 2A). The level of KLF5 was increased in SNU-C4 5-FU 
compared to SNU-C4. Similarly, cyclin D1 and b-catenin were 
also increased (Fig. 2B). 
The changes of cell death protein and KLF5 protein after 
radiation therapy in cell line 
We made a stable cell line with HCT116 which are 
overexpressed of KLF5 (HCT116 KLF5 OE). We performed 
an experiment similar to HCT116 p53+/+ cells, expressing 
endogenous KLF in HCT116 KLF5 OE). The Cells (HCT116 and 
HCT116 KLF5 OE) were subjected to 10-cGy radiation exposure, 
after which cell death protein levels were evaluated. The p53 
was checked for radiation effect. After radiation therapy, cell 
death protein such as BAX, p53, PUMA tends to be increased 
compared to control in both groups. In both cell lines, cyclin 
D1, b-catenin increased proportional to the protein amount of 
KLF5 after radiation. Expected, cyclin D1 and b-catenin were 
increased after radiation, especially this increase was amplified 
in HCT116 KLF5 OE which would be proportional to a mount of 
baseline KLF5 protein (Fig. 3A). 
Lastly, we did MTT assay to assess for cell survival. With 
MTT assay, HCT116 KLF5 OE cells exhibited a significantly 
higher survival rate compared to control HCT116 cells (P < 0.05), 
further suggesting that KLF5 mediates cell survival (Fig. 3B). 
DISCUSSION
This study was to investigate the biomarker, predictive of 
response of preoperative chemotherapy in rectal cancer using 
Table 3. Univariate and multivariate analysis of clinical variation and biomarker associated pCR 
 Variable
Univariate analysis Multivariate analysis
Yes (n = 9) No (n = 51) P­value Yes (n = 9) No (n = 51) P­value
Age (yr)
   ≤60 8 26 0.064
   >60 1 25
Sex
   Male 8 41 1.0
   Female 1 10
Pre­CRT CEA
   ≤5 7 29 0.29
   >5 2 22
Clinical T stage
   cT2/cT3 7 43 0.63
   cT4 2 8
Clinical N stage
   cN (­) 5 26 1.00
   cN (+) 4 25
EGFR
   N/1+ 9 35 0.048 9 35 0.40
   2+/3+ 0 16 0 9
Ki67
   High 6 38 0.44
   Low 3 13
p53
   Positive 2 24 0.089
   Negative 7 27
C­ern
   N/1+ 7 42 0.66
   2+/3+ 2 9
KLF5
   High 2 34 0.023 2 34 0.012
   Low 7 17 7 17
pCR, pathologic complete remission; CRT, chemoradiation therapy; EGFR, epidermal growth factor receptor; KLF, Krüppel­like factor.
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the IHC stain, which is the easiest and quickest method. In 
this study, we have found that a novel factor, KLF5 as a poor 
prognosis factor for T-down staging, but it is an unfamiliar 
biomarker. So, we did experimental in vitro study why KLF5 
expression is related with resistance to chemo or radiation 
therapy. In vitro, we found that the KLF5 is located downstream 
of the KRAS mutation and protein KLF5 is stabilized by chemo 
or radiation therapy, increasing the cell cycling protein such as 
cyclin D1 or cell proliferation protein such as b-catenin, which 
is predicted to be related to cell survival. 
In recent years, several promising candidate markers have 
been reported potential roles in the prediction of radiation 
response, including angiogenesis (thymidine phosphorylase, 
thymidylate synthase), and vascular endothelial growth factor, 
proliferation (cyclooxygenase-2 and proliferating cell nuclear 
antigen) and cell adhesion or collagenase (CD44, CD133, matrix 
metalloproteinase [MMP] 2, and MMP9) and apoptosis (bax, 
p53, nuclear factor-kappa B [NfkB], and surviving) with regard 
to preoperative CRT in rectal cancer [19,20]. Also, few studies 
have evaluated KRAS as a biomarker for tumor response in 
rectal cancer patients treated with CRT and TME. Garcia-Aguilar 
et al. [21] described a series of rectal cancer patients treated 
with preoperative CRT and reported that tumors with wild-type 
KRAS were more likely to respond to CRT than tumors with 
mutant KRAS. 
KRAS mutation was reported 35%–40% in previous studies 
Table 4. Comparison of clinicopathologic factors according 
to KLF5 intensity
Variable No. Low intensity (n = 24)
High intensity 
(n = 36) P­value
ypT stage
   ypT0–1 23 14 9 0.009
   ypT2–3 37 10 27
ypN stage
   ypN0 44 18 26 0.812
   ypN+ 16 6 10
pCR
   Complete 9 7 2 0.023
   Partial 51 17 34
KRAS
   Wild 51 23 28 0.055
   Mutated 9 1 8
Pre CEA
   ≤5 36 16 20 0.432
   >5 24 8 16
TNM stage
   Stage 0–I 30 14 15 0.206
   Stage II–III 30 10 21
KLF, Krüppel­like factor; pCR, pathologic complete remission.
Fig. 1. KLF5 and up/down­stream on colon cancer cell line. 
(A) Western of KLF5 expression depends on KRAS and BRAF 
mutation. (B) The protein expressed at the downstream of 
KLF5 with KRAS or without KRAS mutation cell line. KLF, 
Krüppel­like factor; WT, wild type.
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 [22,23] although we just observed only just 15%. As PETACC-8 
already demonstrated, KRAS mutation is most important 
factor in treatment in colorectal cancer [24]. But, most of study 
showed KRAS mutation has no significant as a prognostic 
factor in preoperative CRT. As our data demonstrated, KRAS 
mutation tended to predict tumor regression grade but not 
has significance. Instead, KLF5 expression in IHC straining 
predict CRT response efficiently not only tumor regression, 
but also pathologic complete remission. The KLF5 is a zinc 
finger-containing transcription factor that is involved in 
diverse physiological processes including proliferation and 
differentiation of intestinal epithelial cells [16]. KLF5 is known 
to be increased by oncogenic KRASV12 and the BRAF-ERK-MEK 
cascade [18]. KLF5 has a pro-proliferative effect in cultured 
cells through activation of cell cycle regulatory proteins such 
as cyclin D1, cyclin B1, and Cdc2 [16-18]. Here, we made a 
hypothesis that each mutation of RAS, RAF, MER, ERK also 
influence the results of chemoradiation response, so, molecule 
of downstream such like KLF5 would be more specific to 
predict CRT response. KLF5 is known to be a crucial role in 
the maintenance of cellular proliferation, cyto-differentiation, 
and morphology of the crypt-villus axis [25,26]. And it is 
amplified in colorectal cancers suggesting a contributory role in 
tumorigenesis to regulate cell cycle components such as Cyclin 
D1, Cyclin B1, and Cdc2 [16,25]. 
Our in vitro, we want to validate the independent role of 
KLF5 with stress. Previous report showed the increase of KLF 5 
protein stability depends on dose of chemotherapy [27]. Same 
as previous report, protein level of KLF5 is increased as dose 
dependent with radiation therapy was inducted, in HCT116 
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which has KRAS mutation. We select Caco-2 cell line, which 
has wild type KRAS but just has a few levels of KLF5 protein. 
Interestingly, Caco-2 showed same tendency of increasing 
protein of KLF5 as time or dose dependent with treated 5-FU 
chemotherapy. We had a conclusion; a protein of KLF5 is 
directly influenced by stress. Here, important data was that the 
baseline protein level of KLF5 has decisive effect when stress 
(radiation, chemotherapy) would be added. Long exposure of 
5-FU in SNU-C4 getting chemo-resistance showed high protein 
level of KLF5, sequentially increasing cyclin D1, b-catenin. We 
thought that KLF5 expression would trigger cell cycle activation 
via cyclin D1 or cyclin B1/CdC [16] and maintain bonding each 
other or adhesion another site via b-catenin. We preliminary 
suggest the positive role of KLF5 for to survive from CRT via 
increasing cyclin D1 related with cell cycle, b-catenin related 
with cell proliferation.
We made stable cell line with HCT116 which gets overexpress 
of KLF5. We made a stress with 10-cGy radiation in both 
HCT116 and HCT116 KLF5 OE. After 24 hours, HCT116 KLF 
OE showed apoptosis markers such as bax, P53, PUMA. The 
cyclin D1 or b-catenin amplified by chemotherapy for survival 
especially in HCT116 KLF OE. In MTT assay, HCT116 KLF5 
OE stable cell line showed significantly better cell viability 
compared to control cells, suggesting that KLF5 mediates cell 
survival. We just analogize KLF5 has a potential role to survive 
following threatening signal, via promoting cell cycle through 
cycle D1, B1/CdC. 
A recent systemic review emphasized neoadjuvant CRT 
should be considered in patients with high-risk locally 
advanced rectal cancer to reduce local recurrence and distant 
failure [28]. However, as mentioned above, 15%–30% of patients 
still progress while being treated with CRT or go on to develop 
distant metastasis, require different treatment regimen. 
Therefore, patients with poor response should be well selected, 
and required personalized treatment. Recently the important 
biomarker such as BRAF, SMAD4 gene mutation and polo-
like kinase 1 expression [29,30] are discussed to predict poor 
response to CRT and to clarify the mechanism of chemoradio-
resistance. This mechanism studies could help to develop new 
therapeutic target to increase the response rate of CRT, and 
this ongoing effort will open a new chapter in rectal cancer 
treatment. 
Our study has several limitations. First pathologic complete 
remission rate is just 15%, lower results than other papers. We 
needed more than 8 times biopsy for IHC before radiation. So, 
small sized rectal cancer could not be enrolled in this study. 
Second, it is retrospective study with low sample size to make 
a conclusion. Third, the use of KLF5 as a predicative biomarker 
may be limited because it affects T-down staging but not 
N-down staging. However, since KLF5 is a poor prognostic factor 
for T-down staging, it does not matter even if it is not related 
with N-down staging. Lastly, the experimental studies for 
evaluating mechanism are insufficient to conclude that KLF5 
protein was directly related with chemoradio-resistance, but the 
attempt to indirectly suggest the mechanism of chemoradiation 
resistance is thought to be meaningful. 
To the best of our knowledge, our study is the first article to 
explain the mechanism how tumor can survive in threatened 
stress like CRT. We found that protein of KLF5 which related 
with KRAS, BRAF mutation is a potential mediator to resist CRT 
in rectal cancer. And that reason, KLF5 expression was could 
be a specific biomarker to predict poor TRG response after CRT 
in rectal cancer patients. We thought KLF5 protein has been 
amplified following CRT and disturb tumor down grading 
to make active cell cycle via cyclin D1, cyclin B1 and Cdc2 or 
b-catenin.
In conclusion, overexpression of KLF5 in pretreatment 
biopsies might be predictive factor of poor tumor regression 
after preoperative CRT. KLF5 was significantly related with 
KRAS mutation but, KLF5 has an independent role to get 
resistance from preoperative CRT. Our study suggested one 
possible mechanism of biomarker to predict chemoradiation 
response.
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